Key terms
About CLLS
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CLLS news
Today
8:00am ET
Cellectis Announces Leadership Shift in Finance
Today
12:55am ET
Cellectis SA: Strong Investment and Clinical Progress Signaling a Market Outperform Rating
Yesterday
2:45am ET
Analysts Are Bullish on Top Healthcare Stocks: Qiagen (QGEN), Inari Medical (NARI)
Apr 30
5:35am ET
Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Cellectis SA (CLLS) and Idexx Laboratories (IDXX)
Apr 30
5:33am ET
Barclays Remains a Buy on Cellectis SA (CLLS)
Apr 29
4:48pm ET
Cellectis reports Q1 EPS (59c), consensus (22c)
Apr 22
5:27pm ET
Cellectis Unveils Groundbreaking Gene-Editing Advances
Apr 10
4:33pm ET
Cellectis publishes new research paper in Molecular Therapy
Apr 08
4:57pm ET
Cellectis Unveils Breakthrough Gene-Editing Innovations
No recent press releases are available for CLLS
CLLS Financials
Key terms
Ad Feedback
CLLS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CLLS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range